Names and pronunciation
(a-va-KOE-pan) Tavneos
PDF page 128
Loading InternPractice…
Drug reference
(a-va-KOE-pan) Tavneos
PDF page 128
Func. class.: Immunomodulating agent
PDF page 128
Chem. class.: Complement 5a receptor (C5aR) antagonist
PDF page 128
ACTION: Blocks C5a-mediated neutrophil activa- tion and migration. The precise mecha- nism is unknown
PDF page 129
USES: Antineutrophil cytoplasmic autoantibody (ANCA)–associated vasculitis in combi nation
PDF page 129
CONTRAINDICATIONS Hypersensitivity Precautions: Hepatotoxicity, angio- edema, hepatitis B virus reactivation, serious infections
PDF page 129
SIDE EFFECTS CNS: Headache, paresthesia, fatigue, dizziness GI: Nausea, diarrhea, vomiting, abdomi- nal pain CV: Hypotension INTEG: Rash
PDF page 129
INTERACTIONS Avoid use with strong and moderate CYP3A4 enzyme inducers, strong CYP3A4 enzyme inhibitors: Reduce avacopan dose to 30 mg daily Sensitive CYP3A4 substrates: Monitor for adverse reactions and reduce dose of sensitive CYP3A4 substrates
PDF page 129
DOSAGE AND ROUTES • Adult: PO 30 mg (three 100 mg cap- sules bid with food; reduce to 30 mg daily when used with strong CYP3A4 inhibitors
PDF page 129
Available forms: Capsule 10 mg
PDF page 129
Administer: • Capsules should not be crushed, chewed, or opened • If a dose is missed, wait until the usual scheduled time to take the regular dose, do not double
PDF page 129
Assess: • Monitor LFTs, alkaline phosphatase, total bilirubin baseline • Monitor hepatitis B virus (HBV) serol- A ogy: Screen patients for HBV infection by measuring HBsAg and anti-HBc baseline
PDF page 129
Evaluate: • Therapeutic response: Decreasing vasculitis
PDF page 129
Patient and caregiver information: • Instruct the patient to swallow whole, not to chew or crush. If a dose is missed, take at next regular dose time, to discuss all OTC, Rx, and herbals taken • Hypersensitivity: Advise patients to seek immediate medical attention for an- gioedema (swelling of face, extremities, eyes, lips, tongue; and difficulty in swal- lowing or breathing) and to stop the drug immediately • Hepatotoxicity: Advise patients to contact their health care provider imme- diately for signs or symptoms of liver problems; yellowing of the skin or the white part of the eyes, dark or brown urine, pain on the upper right side of the abdomen, bleeding or bruising anywhere • Infections: Inform patients that seri- ous infections have been reported, includ- ing reactivation of hepatitis B infection. Instruct patients to contact their health care provider immediately if they develop any signs or symptoms of an infection • Breastfeeding: Teach patient to con- sider benefits/risk during breastfeeding
PDF page 129
PHARMACOKINETICS Protein binding: 99.99% NURSING CONSIDERATIONS
PDF page 129
• Adult: PO 30 mg (three 100 mg cap- sules bid with food; reduce to 30 mg daily when used with strong CYP3A4 inhibitors
PDF page 129